Navigation Links
Luminex Corporation Reports Third Quarter 2010 Results

AUSTIN, Texas, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX) today announced financial results for the third quarter and nine months ended September 30, 2010.  Financial and operating highlights include the following:

  • Consolidated third quarter revenue was $33.9 million, a 16 percent increase over the third quarter of 2009
  • Luminex launched new MAGPIX® multiplexing system bringing affordable multiplexing to laboratories worldwide
  • Third quarter 2010 shipments of 231 multiplexing analyzers that included 41 MAGPIX systems, resulting in cumulative life-to-date multiplexing analyzer shipments of 7,414, up 14% from a year ago. This compares to shipments of 259 multiplexing analyzers in the third quarter of 2009. Also included in system sales are 28 BSD sample handling systems
  • Consolidated gross profit margin was 65 percent for the third quarter of 2010
  • Operating income for the third quarter of 2010 was $155,000 compared with an operating loss of $512,000 for the same period last year
  • Received FDA clearance for CYP450 2D6 assay, the first multiplexed assay addressing the area of Personalized Medicine. The company plans to launch the 2D6 assay by year end
  • Won prestigious 2010 Prix Galien USA Award for Luminex's innovative xTAG® Respiratory Viral Panel (RVP) named "Best Medical Technology"

  • REVENUE SUMMARY(in thousands, except percentages)Three Months EndedSeptember 30,Variance20102009($)(%)(in thousands, except percentages)System sales

    (1,081)-12%Consumable sales

    8,6336,0622,57142%Royalty revenue

    5,6604,69996120%Assay revenue

    7,8636,1991,66427%All other revenue

    4,75516%Nine Months EndedSeptember 30,Variance20102009($)(%)(in thousands, except percentages)System sales

    ,2766%Consumable sales

    28,15020,3477,80338%Royalty revenue

    16,37013,5242,84621%Assay revenue

    22,96218,1644,79826%All other revenue

    82,476$   17,89122%Consolidated revenue for the third quarter of 2010 was $33.9 million, a 16 percent increase over consolidated revenue of $29.1 million for the third quarter of 2009.  GAAP net loss for the third quarter of 2010 was $727,000, or $0.02 per share, compared with a GAAP net loss of $609,000, or $0.01 per share, for the prior year period.  Net income for the third quarter of 2010 included non-cash charges of $2.3 million in stock compensation expense associated with ASC 718 and $2.2 million of depreciation and amortization expense.  Net income for the third quarter of 2009 included non-cash charges of $2.2 million in stock compensation expense associated with ASC 718 and $2.1 million of depreciation and amortization expense.  A portion of our total valuation allowance on U.S. deferred tax assets was released at December 31, 2009 and, as a result, the 2010 third quarter and year to date results are shown fully taxed in the U.S., whereas the 2009 third quarter and year to date results are not.  On a comparable basis, net loss for the third quarter of 2009, removing the effects of the release of the valuation allowance and the $4.4 million litigation settlement in 2009, would have been $1.4 million or a loss of $0.04 per share, and the net loss for the first nine months of 2009 would have been $1.9 million, or a loss of $0.05 per share.

    LUMINEX CORPORATIONREPORTABLE SEGMENT HIGHLIGHTS(unaudited)(in thousands)Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009RevenueTechnology and strategic partnerships

    $  24,593$  22,031$  75,036$  62,595Assays and related products

    9,2807,08725,33119,881Total Revenue

    33,87329,118100,36782,476Operating income (loss)Technology and strategic partnerships

    2,19354910,1055,453Assays and related products

    (2,038)(1,061)(3,937)(3,352)Total Operating income (loss)

    155(512)6,1682,101"Luminex delivered a solid financial and operating performance for the third quarter of 2010, though we faced a difficult year-over-year comparison," said Patrick J. Balthrop, president and chief executive officer of Luminex.  "Our consumable, assay, and royalty revenue categories each showed favorable growth trends over a strong performance in the prior year period. We continue to expand our installed base and are especially excited about the early demand seen for our recently launched MAGPIX® system." 

    "During the quarter we also made good progress on our product development initiatives.  Luminex is on-track with the integration of our recent acquisition, BSD Robotics, and in October we signed a worldwide OEM agreement with the Tecan Group to develop a new automated newborn screening solution," added Balthrop. "These initiatives along with our investment in exciting new products, such as our innovative MAGPIX instrument, will help ensure that Luminex maintains our edge in the marketplace, delivers high performance solutions to our customers, and drives long term value for our shareholders."

    "We look forward to finishing the year with a strong fourth quarter performance," Balthrop concluded. 

    FINANCIAL OUTLOOK AND GUIDANCE The Company expects to deliver consolidated 2010 revenue of between $138 and $140 million, representing an increase of 14 to 16 percent over reported 2009 annual revenue.

    CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2010, on Thursday, November 4, 2010, at 4:00 p.m. Central time/ 5:00 p.m. Eastern time.  The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

    Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.  The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at

    Statements made in this release that express Luminex' or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base; demand for our MAGPIX system; integration of BSD Robotics; our relationship with Tecan Group; our investment in new products and our ability to maintain our edge in the marketplace, deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2010 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex' actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex' products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex' ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex' foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex' Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2010 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.



    Harriss T. Currie

    Matthew ScaloVice President, Finance and Chief Financial Officer

    Sr. Director of Investor Relations512-219-8020 LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)September 30,December 31,20102009(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    90,843Restricted cash

    1,001-Short-term investments

    27,9398,511Accounts receivable, net

    19,01322,108Inventories, net

    24,13617,524Deferred income taxes

    2,7751,040Prepaids and other

    2,6262,130Total current assets

    156,719142,156Property and equipment, net

    21,22817,255Intangible assets, net

    13,42712,938Deferred income taxes

    10,61014,732Long-term investments



    3,8721,087Total assets

    248,013LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    8,430Accrued liabilities

    6,3367,493Deferred revenue

    4,3462,967Current portion of long term debt


    33-Total current liabilities

    18,18619,758Long-term debt

    3,4043,591Deferred revenue


    3,3131,312Total liabilities

    29,37629,275Stockholders' equity:Common stock

    4141Additional paid-in capital

    293,500285,648Accumulated other comprehensive gain

    1,06828Accumulated deficit

    (64,947)(66,979)Total stockholders' equity

    229,662218,738Total liabilities and stockholders' equity

    248,013LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009(unaudited)(unaudited)Revenue

    $  33,873$  29,118$100,367$  82,476Cost of revenue

    12,01110,34732,56926,837Gross profit

    21,86218,77167,79855,639Operating expenses:Research and development

    5,8165,64316,67415,246Selling, general and administrative

    15,89113,64044,95638,292Total operating expenses

    21,70719,28361,63053,538Income from operations

    155(512)6,1682,101Interest expense from long-term debt

    (106)(116)(334)(358)Other income, net

    159144400593Settlement of litigation

    ---(4,350)Income (loss) before income taxes

    208(484)6,234(2,014)Income taxes

    (935)(125)(4,202)(273)Net income (loss)

    2,032$   (2,287)Net income (loss) per share, basic

    (0.06)Shares used in computing net income (loss) per share, basic

    41,13140,66140,97340,515Net income (loss) per share, diluted

    (0.06)Shares used in computing net income (loss) per share, diluted

    41,13140,66142,23540,515LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009(unaudited)(unaudited)Cash flows from operating activities:Net income (loss)

    (609)$   2,032$  (2,287)Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:Depreciation and amortization

    2,2102,1166,4945,995Stock-based compensation

    2,3192,2316,9255,817Deferred income tax benefit

    985-3,4902Excess income tax benefit from employee stock-based awards

    234-(1,290)-Loss on disposal of assets


    5866768491,257Changes in operating assets and liabilities:Accounts receivable, net

    (1,144)(898)4,066(7,988)Inventories, net

    (2,952)(286)(5,065)(1,108)Other assets

    591405(154)(28)Accounts payable

    1,0441,437(2,422)376Accrued liabilities

    3081,295(1,037)(3,023)Deferred revenue

    450(28)1,190313Net cash provided by (used in) operating activities

    3,9046,33915,078(649)Cash flows from investing activities:Purchases of available-for-sale securities

    (4,998)(12,003)(26,665)(56,649)Maturities of available-for-sale securities

    -17,98616,19322,980Maturities of held-to-maturity securities

    -3,938-40,078Purchase of property and equipment

    (3,113)(3,502)(8,562)(8,618)Business acquisition consideration, net of cash acquired

    --(5,036)-Increase in restricted cash

    --(1,000)-Purchase of cost method investment

    (76)-(2,076)-Acquired technology rights

    --(1,200)(21)Net cash (used in) provided by investing activities

    (8,187)6,419(28,346)(2,230)Cash flows from financing activities:Payments on debt

    --(895)(440)Proceeds from debt

    ---454Proceeds from issuance of common stock

    7771,447362Excess income tax benefit from employee stock-based awards

    (234)-1,290-Net cash (used in) provided by financing activities

    (227)771,842376Effect of foreign currency exchange rate on cash

    (247)(246)(188)(376)Change in cash and cash equivalents

    (4,757)12,589(11,614)(2,879)Cash and cash equivalents, beginning of period

    83,98666,15190,84381,619Cash and cash equivalents, end of period

    $ 79,229$ 78,740$ 79,229$ 78,740LUMINEX CORPORATIONRECONCILIATION OF ADJUSTED NET INCOME TO GAAP NET INCOME(in thousands, except per share amounts)Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009Net income (loss)

    (609)$  2,032$ (2,287)Adjusting items:Settlement of litigation

    ---4,350Income tax adjustment*

    -(817)-(3,958)Adjusted net income (loss)

    (727)$ (1,426)$  2,032$ (1,895)Adjusted net income (loss) per share, basic

    $   (0.02)$   (0.04)$
    .05$   (0.05)Shares used in computing adjusted net income (loss) per share, basic

    41,13140,66140,97340,515Adjusted net income (loss) per share, diluted

    $   (0.02)$   (0.04)$
    .05$   (0.05)Shares used in computing adjusted net income (loss) per share, diluted

    41,13140,66142,23540,515* Income tax adjustment illustrates 2009 financial results without the effect of the release of the valuation  allowance on the U.S. deferred tax assets for comparison to 2010 financial resultsThe Company believes that the non-GAAP measure used in this presentation, when presented in conjunction with the comparable GAAP measure, is useful to both management and investors in analyzing financial and business trends regarding the Company's ongoing business and operating performance. This non-GAAP measure should be considered in addition to, but not as a substitute for, items prepared in accordance with GAAP.


    SOURCE Luminex Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
    2. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
    3. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
    4. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
    5. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
    6. Luminex Corporation to Present at UBS Global Life Sciences Conference
    7. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
    8. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
    9. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
    10. Gentris Corporation Names New Chief Scientific Advisor
    11. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
    Post Your Comments:
    (Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
    (Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
    (Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
    (Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
    (Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
    (Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
    Breaking Medicine News(10 mins):